What Are The Common Medical Intermediates?

What are the common medical intermediates? Pharmaceutical intermediates refer to the chemical raw materials or chemical products used in the pharmaceutical synthesis process. From the perspective of the development history of China's pharmaceutical intermediates industry, after nearly 30 years of development, pharmaceutical intermediates have developed from a small branch of the chemical industry into an emerging industry with an output value of billions of yuan, and the market competition has become increasingly fierce. The following small series for you to introduce several common pharmaceutical intermediates:

N- benzyl-N - methyl ethanolamine
N-benzyl-n-methylethanolamine is an important pharmaceutical intermediate, which can be used to synthesize anti-asthma and anti-allergy drugs, anti-hypertension drug Nicardipine and some new cardiovascular drugs. In addition also can synthesize pesticide herbicide plant fungicide and metal preservative and so on.

4,4 '-methyl dimethoxy acetoacetate
4,4 '-dimethoxyacetoacetate is an important intermediate of nivardipine for the treatment of cardiovascular and cerebrovascular diseases. It is the leading drug for the treatment of cardiovascular and cerebrovascular diseases in the international market at present, and has not been produced in China. Methyl dimethoxy acetate was synthesized from acetalic acid and trimethyl orthoformate in the presence of concentrated sulfuric acid, and the latter reacted with methyl acetate and sodium methanolto get 4,4 '-methyl dimethoxy acetoacetate.

α-methylene cycloketone
α-methylene cycloketone is the active center of many anticancer drugs. It containsα,β-unsaturated ketone, which is a hidden group of anticancer active groups. It is an important intermediate in the synthesis of many important anticancer drugs.

4- propylsulfide o-phenylenediamine
4-propylsulfo-o-phenylenediamine is a key intermediate in the highly effective broad-spectrum deinsectizing drug albendazole, a new drug introduced in the late 1980s that is less toxic to humans and animals and the most potent in benzimidazole.

Palmer azole panitan
Paczopanil is a novel oral angiogenesis inhibitor developed by GlaxosmithKline that targets the vascular endothelial growth factor receptor (VEGFR) and ACTS by inhibiting tumor blood supply to new angiogenesis. It is suitable for the treatment of advanced renal cell carcinoma (a type of renal cancer with cancer cells found in renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC).

2, 4-dichloro-5-methoxyaniline
Bosutinib, developed by Wyeth Pharmaceuticals of the US, was approved in the EU as an "orphan" drug for chronic myeloid leukemia (CML) in September 2010. On September 4, 2012, the drug was approved by the US Food and Drug Administration (FDA) and marketed under the name Bosulif. The European Food and Drug Administration (EMA) endorsement came to market on March 27, 2013, and the PMDA endorsement came to market in Japan on September 26, 2014.